Hepatect

Hepatect is a human hepatitis B immunoglobulin supplied as a solution for injection. The product contains purified anti‑hepatitis B surface antigen antibodies, with strength not specified, and is administered intravenously. It is classified as an immunoglobulin (HBIG) and is available by prescription in the European Union for passive immunization against hepatitis B virus.

Hepatect is used to provide passive immunity against hepatitis B virus in specific clinical situations. - Post‑exposure prophylaxis for individuals with potential hepatitis B exposure who have not completed vaccination. - Prevention of hepatitis B recurrence after orthotopic liver transplantation. - Protection of patients with chronic liver disease who are undergoing immunosuppressive therapy. - Adjunctive prophylaxis in newborns of hepatitis B‑positive mothers when vaccine response is inadequate. - Supplementation for individuals with inadequate response to hepatitis B vaccine series.

Adverse reactions to Hepatect are generally mild to moderate, but serious events can occur. Common: - Injection site discomfort or erythema. - Mild fever or chills following administration. - Headache or fatigue within 24 hours. Serious: - Anaphylactic or severe allergic reactions, including urticaria and bronchospasm. - Acute hemolysis or transfusion‑related acute lung injury (TRALI). - Severe hypotension or cardiovascular collapse.

Healthcare providers should consider several precautions when prescribing Hepatect. - Assess patient history for prior allergic reactions to blood products or immunoglobulins. - Monitor vital signs during and after infusion, especially in patients with cardiovascular disease. - Use caution in pregnant or breastfeeding individuals; safety data are limited. - Adjust dosing in patients with renal impairment, as clearance may be reduced. - Ensure hepatitis B surface antigen status is confirmed before administration. - Document any adverse events and report serious reactions to pharmacovigilance authorities.

Hepatect may interact with other agents, requiring careful management. Avoid: - Concurrent administration of other immunoglobulin products that could increase the risk of hyperviscosity. - Live vaccines administered within 4 weeks of Hepatect, as passive antibodies may interfere with vaccine efficacy. Use with caution: - Anticoagulants, because infusion may affect coagulation parameters. - Immunosuppressive drugs, which could alter the duration of passive immunity. - High‑dose steroids, potentially affecting antibody metabolism. - Renal‑clearing drugs, as volume load from infusion may impact renal function.